SLC9A7: A Potent Drug Target and Potential Biomarker for the Treatment of Electrolyte Imbalances

Target Name: SLC9A7

NCBI ID: G84679

SLC9A7

SLC9A7: A Potent Drug Target and Potential Biomarker for the Treatment of Electrolyte Imbalances

Introduction

Sodium-dependent and sodium-exchangeable potassium channels are critical for maintaining the resting membrane potential of cells and regulating various physiological processes, including muscle and nerve function. The SLC9A7 gene, located on chromosome 11.2, encodes a non-selective sodium potassium/proton exchanger (NSAP), which is essential for maintaining electrolyte balance in the body. NSAPs are transmembrane proteins that span the endoplasmic membrane and play a crucial role in the regulation of intracellular ion levels. In addition to its role in electrolyte balance, NSAPs are also involved in various signaling pathways and are potential drug targets for the treatment of various physiological disorders.

SLC9A7 function and structure

The SLC9A7 gene encodes a 124-kDa protein that consists of two main domains: the N-terminus and the C-terminus. The N-terminus domain is responsible for the NSAP-related functions, such as ion transport and-dependent potassium channels. These functions are critical for maintaining the resting membrane potential of cells and regulating various physiological processes, including muscle and nerve function.

The C-terminus domain is responsible for the NSAP-related signaling pathways. This includes the regulation of ion channels, protein-protein interactions, and intracellular signaling pathways. The C-terminus domain also contains a unique structural feature known as a \"calcium -binding module,\" which is involved in the regulation of intracellular calcium levels.

Expression and function

NSAPs are widely expressed in various tissues and organs, including brain, heart, muscle, and kidney. They are involved in the regulation of various physiological processes, including muscle and nerve function, as well as the regulation of ion levels in the body.

In addition to its role in physiological processes, NSAPs are also involved in the development of various diseases, including epilepsy, migraine, and heart failure. For example, studies have shown that individuals with certain genetic variations in the SLC9A7 gene are at an increased risk for developing epilepsy.

Drug targeting

SLC9A7 is a potential drug target for the treatment of various physiological disorders due to its involvement in the regulation of ion levels and various signaling pathways. Drugs that target NSAPs, such as open-label anti-neuron-specific Na+ channel blockers (SLX -089), can significantly reduce brain activity in patients with epilepsy, thereby improving the clinical symptoms of epileptic seizures.

Conclusion

SLC9A7 is a non-selective sodium potassium/proton exchanger that is essential for maintaining the resting membrane potential of cells and regulating various physiological processes. Its involvement in various signaling pathways and its potential as a drug target make it an attractive target for the treatment of various physiological disorders. Further research is needed to fully understand the role of NSAPs in the regulation of ion levels and various physiological processes, as well as their potential as drug targets.

Protein Name: Solute Carrier Family 9 Member A7

Functions: Golgi Na(+), K(+)/(H+) antiporter. Mediates the electoneutral influx of Na(+) or K(+) in exchange for H(+). May contribute to the regulation of Golgi apparatus volume and pH

The "SLC9A7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC9A7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets